Invion Ltd. (ASX: IVX) is a clinical-stage drug development company in the biotechnology and pharmaceutical industry in Australia. IVX has three key development programs: INV102 for inflammatory respiratory disease; INV104, a leukotriene receptor antagonist; and, INV103, a modified, naturally occurring human protein.
.svg "close (3)"){kind=small}
